pharma · Non-transfusion-dependent Thalassemia · Advanced Solid Tumors · SLN
Silence Therapeutics
Silence Therapeutics plc
Silence Therapeutics patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 1999
- Employees
- 91
- Programs
- 8
- Drugs
- 6
- Patents
- 3
Silence Therapeutics patents
3 pharmaceutical patents indexed for Silence Therapeutics. 0 expire within 24 months.
Silence Therapeutics has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Silence Therapeutics have?
3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Silence Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.